mazindol
Trade name: sanorex
Approved
Jun 14, 1973
Mazindol is an amphetamine-like medicine which was developed by Sandoz in 1967 and approved by FDA for the treatment of obesity and Duchenne muscular dystrophy under the names Sanorex and Mazanor. The exact mechanism of action is unknown, but possibly involves the stimulation of beta-adrenergic receptors and inhibition of monoamine reuptake. Both Sanorex and Mazanor were withdrawn from the market by reason other than safety. NLS Pharma now is developing mazindol for Attention Hyperactivity Disorder in adults (phase II). — NCATS
Clinical trial activity
5 trials · 4 clinical orgs · 4 marketing orgs
Earliest trial started Sep 1, 1994 (NCT00000277)
Timeline
1970s
1980s
- Aug 28, 1980
American Home Products — NDA Secondary Org
1990s
- Jan 1, 1994
Earliest Phase 2 Sponsor(trial)
2020s
- Jan 1, 2024
Earliest Phase 3 Sponsor(trial)
Indications
Mechanism of action
Approval history
- approvedJun 14, 1973
Chemistry & pharmacology
SMILES
OC1(N2CCN=C2C3=C1C=CC=C3)C4=CC=C(Cl)C=C4- Mol. weight
- 284.74 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Availability
- Discontinued
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaMazindol ↗
- NCATSC56709M5NH ↗
- ChEMBLCHEMBL781 ↗
- ChEMBLCHEMBL2313755 ↗
- ChEMBLCHEMBL2079699 ↗
Also known as
- 42-548
- mazanor
- mazanor
- mazanor
- mazildene
- mazindol
- mazindol
- mazindol
- mazindol
- mazindol
- mazindol
- mazindol
- mazindol
- mazindol
- mazindol
- mazindol
- mazindol
- mazindolo
- mazindolo
- mazindolum
- mazindolum
- sanorex
- sanorex
- sanorex
- teronac
- teronac
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05914194 | Phase 3 | Jan 15, 2024 | NLS Pharma Inc. |
| NCT05055024 | Phase 2 | Nov 1, 2021 | NLS Pharma Inc. |
| NCT04923594 | Phase 2 | Sep 13, 2021 | NLS Pharma Inc. |
| NCT02808104 | Phase 2 | Aug 1, 2016 | NLS Pharma Inc. |
| NCT00000277 | Phase 2 | Sep 1, 1994 | Department of Veteran Affairs, National Institute on Drug Abuse (NIDA), Yale University |
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NLS Pharma Inc. | For profit | 4 | 4 | 2 | 2016 |
| Department of Veteran Affairs | Government | 1 | 0 | 1 | 1994 |
| National Institute on Drug Abuse (NIDA) | Government | 1 | 0 | 1 | 1994 |
| Yale University | Academic/Hospital | 1 | 1 | 1 | 1994 |
Marketing (5)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| American Home Products | For profit | NDA2 | Aug 28, 1980 |
| Hexim | For profit | MKTG | Jun 14, 1973 |
| Novartis | For profit | MKTG | Jun 14, 1973 |
| Novartis | For profit | NDA2 | Jun 14, 1973 |
| Sandoz | For profit | NDA | Jun 14, 1973 |